CELLULAR THERAPY OF CANCER WITH TUMOR PRIMED ANTI CD3 ACTIVATED LYMPHOCYTES

我们假设，接种混合了卡介苗的自体肿瘤细胞的患者将在疫苗部位的引流淋巴结内诱导T细胞免疫反应。为了验证这一假设，晚期恶性肿瘤患者被接种照射后的自体肿瘤细胞与卡介苗皮内混合，并在一周后切除引流淋巴结进行体外激活。在一段时间的激活后，这些细胞在接受IL-2治疗的同时被重新注入患者体内。到目前为止，在11名黑色素瘤患者和12名肾癌患者中，我们已经证明了产生高度特异的疫苗激活的T淋巴细胞对自体肿瘤起反应的能力。在这些患者中，有一些患者在过继移植细胞后肿瘤显著消退。我们继续在晚期肾癌患者中进行这项研究，以期将T细胞的体外免疫功能与体内肿瘤反应性联系起来。

We hypothesize that the vaccination of patients with autologous tumor cells admixed with BCG will induce a T cell immune response within draining lymph nodes from the site of the vaccine. To test this hypothesis, patients with advanced malignancies are vaccinated with irradiated autologus tumor cells admixed with BCG intradermaly and the draining lymph nodes removed one week later for ex vivo activation. After a period of activation, the cells are reinfused into the patients along with the administration of IL-2. To date, in 11 melanoma patients and 12 renal cell cancer patients we have documented the ability to generate highly specific vaccine-primed T lymphocytes reactive to autologous tumor. Significant tumor regression has been noted in some of these patients after adoptive transfer of the cells. We are continuing this study in advanced renal cell cancer patients to correlate in vitro immunological function of T cells with in vivo tumor reactivity.